Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: An independent prognostic marker of survival in colorectal cancer

Human Pathology

Volumn 43, Issue 8, 2012, Pages 1314-1321

  Stenzinger, Albrecht ^a   Von Winterfeld, Moritz ^b   Rabien, Anja ^b   Warth, Arne ^a   Kamphues, Carsten ^b   Dietel, Manfred ^b   Weichert, Wilko ^a   Klauschen, Frederick ^b   Wittschieber, Daniel ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Colorectal cancer; Matrix metalloproteinase; RECK

Indexed keywords

MEMBRANE PROTEIN; RECK PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TISSUE MICROARRAY;

AGED; AGED, 80 AND OVER; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; GPI-LINKED PROTEINS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863984419     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.10.012     Document Type: Article

References (40)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
3. S. Cotton, L. Sharp, and J. Little The adenoma-carcinoma sequence and prospects for the prevention of colorectal neoplasia Crit Rev Oncog 7 1996 293 342
4. P.B. Paty, and A.M. Cohen The adenoma-carcinoma sequence in colorectal neoplasia Gastroenterologist 1 1993 274 286
5. T.P. Pretlow, B.J. Barrow, and W.S. Ashton Aberrant crypts: putative preneoplastic foci in human colonic mucosa Cancer Res 51 1991 1564 1567
6. K.M. Sullivan, and P.S. Kozuch Impact of KRAS mutations on management of colorectal carcinoma Patholog Res Int 2011 (online). Available at: http://www.hindawi.com/journals/pri/2011/219309/
7. E. Vakiani, and D.B. Solit KRAS and BRAF: drug targets and predictive biomarkers J Pathol 223 2011 219 229
8. S. Stintzing, V. Heinemann, A. Jung, N. Moosmann, W. Hiddemann, and T. Kirchner The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status Dtsch Arztebl Int 106 2009 202 206
9. J.S. Ross, J. Torres-Mora, N. Wagle, T.A. Jennings, and D.M. Jones Biomarker-based prediction of response to therapy for colorectal cancer: current perspective Am J Clin Pathol 134 2010 478 490
10. M.E. Lukashev, and Z. Werb ECM signalling: orchestrating cell behaviourand misbehaviour Trends Cell Biol 8 1998 437 441 (Pubitemid 28529716)
11. H. Kataoka, H. Tanaka, K. Nagaike, S. Uchiyama, and H. Itoh Role of cancer cell-stroma interaction in invasive growth of cancer cells Hum Cell 16 2003 1 14
12. J.E. Koblinski, M. Ahram, and B.F. Sloane Unraveling the role of proteases in cancer Clin Chim Acta 291 2000 113 135 (Pubitemid 30089760)
13. M. Egeblad, and Z. Werb New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 2002 161 174 (Pubitemid 37328786)
14. M. van der Jagt, T. Wobbes, L. Strobbe, F. Sweep, and P. Span Metalloproteinases and their regulators in colorectal cancer J Surg Oncol 101 2010 259 269
15. L.M. Coussens, and Z. Werb Matrix metalloproteinases and the development of cancer Chem Biol 3 1996 895 904 (Pubitemid 27017088)
16. C. Gialeli, A.D. Theocharis, and N.K. Karamanos Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting FEBS J 278 2011 16 27
17. X. Li, and J.F. Wu Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs) Recent Pat Anticancer Drug Discov 5 2010 109 141
18. J. Oh, R. Takahashi, and S. Kondo The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis Cell 107 2001 789 800 (Pubitemid 34033671)
19. C. Takahashi, Z. Sheng, and T.P. Horan Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK Proc Natl Acad Sci U S A 95 1998 13221 13226 (Pubitemid 28509552)
20. T. Miki, A. Shamma, and S. Kitajima The β1-integrin-dependent function of RECK in physiologic and tumor angiogenesis Mol Cancer Res 8 2010 665 676
21. B. Welm, J. Mott, and Z. Werb Developmental biology: vasculogenesis is a wreck without RECK Curr Biol 12 2002 R209 211
22. T. Masui, R. Doi, and T. Koshiba RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis Clin Cancer Res 9 2003 1779 1784 (Pubitemid 36554604)
23. P.N. Span, C.G. Sweep, P. Manders, L.V. Beex, D. Leppert, and R.L. Lindberg Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma Cancer 97 2003 2710 2715 (Pubitemid 36605137)
24. M. Pesta, V. Kulda, and O. Topolcan Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC Anticancer Res 29 2009 4535 4539
25. D. Wittschieber, A. Stenzinger, and F. Klauschen Decreased RECK and increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness Pathobiology 78 2011 123 131
26. A. Rabien, M. Burkhardt, and M. Jung Decreased RECK expression indicating proteolytic imbalance in prostate cancer with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy Eur Urol 51 2007 1259 1266 (Pubitemid 46436286)
27. K. Takenaka, S. Ishikawa, and Y. Kawano Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer Eur J Cancer 40 2004 1617 1623 (Pubitemid 38757753)
28. K. Furumoto, S. Arii, and A. Mori RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance Hepatology 33 2001 189 195 (Pubitemid 32016901)
29. T. Takeuchi, M. Hisanaga, and M. Nagao The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer Clin Cancer Res 10 2004 5572 5579 (Pubitemid 39100498)
30. M.F. van der Jagt, F.C. Sweep, and E.T. Waas Correlation of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and extracellular and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer Cancer Lett 237 2006 289 297 (Pubitemid 43777076)
31. W. Remmele, and H.E. Stegner Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue Pathologe 8 1987 138 140
32. L.M. McShane, D.G. Altman, and W. Sauerbrei REporting recommendations for tumor MARKer prognostic studies (REMARK) Exp Oncol 28 2006 99 105 (Pubitemid 44140259)
33. F.A. Haggar, and R.P. Boushey Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors Clin Colon Rectal Surg 22 2009 191 197
34. A. Jemal, L.X. Clegg, and E. Ward Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival Cancer 101 2004 3 27 (Pubitemid 38812419)
35. V. Deschoolmeester, M. Baay, P. Specenier, F. Lardon, and J.B. Vermorken A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy Oncologist 15 2010 699 731
36. N. Knijn, J. Tol, and C.J. Punt Current issues in the targeted therapy of advanced colorectal cancer Discov Med 9 2010 328 336
37. S. Zucker, J. Cao, and W.T. Chen Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 19 2000 6642 6650 (Pubitemid 32197703)
38. T.H. Vu, and Z. Werb Matrix metalloproteinases: effectors of development and normal physiology Genes Dev 14 2000 2123 2133
39. S. Kitajima, T. Miki, and Y. Takegami Reversion-inducing cysteine-rich protein with Kazal motifs interferes with epidermal growth factor receptor signaling Oncogene 30 2011 737 750
40. C.Y. Cho, J.H. Wang, H.C. Chang, C.K. Chang, and W.C. Hung Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells J Cell Physiol 213 2007 65 69